Trial Outcomes & Findings for A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema (NCT NCT04797390)

NCT ID: NCT04797390

Last Updated: 2026-03-02

Results Overview

The change in average site score from baseline assessed via endoscopy using the Modified Patterson Scale. The range for each site was 0-3: Normal, Mild, Moderate, Severe. A lower score means a better outcome.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

236 participants

Primary outcome timeframe

Change from Baseline at 2 months, 4 months, 6 months

Results posted on

2026-03-02

Participant Flow

Participant milestones

Participant milestones
Measure
Advanced Pneumatic Compression Device (APCD)
Daily self-administered treatment with the Flexitouch® Plus system (FT)
Usual Care
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
Overall Study
STARTED
119
117
Overall Study
Baseline Visit
116
105
Overall Study
2-month Visit
108
94
Overall Study
4-month Visit
101
88
Overall Study
COMPLETED
101
87
Overall Study
NOT COMPLETED
18
30

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Advanced Pneumatic Compression Device (APCD)
n=119 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
Usual Care
n=117 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
Total
n=236 Participants
Total of all reporting groups
Age, Continuous
62.7 Years
STANDARD_DEVIATION 9.8 • n=41 Participants
60.9 Years
STANDARD_DEVIATION 11.9 • n=35 Participants
61.8 Years
STANDARD_DEVIATION 10.9 • n=76 Participants
Sex: Female, Male
Female
26 Participants
n=41 Participants
32 Participants
n=35 Participants
58 Participants
n=76 Participants
Sex: Female, Male
Male
93 Participants
n=41 Participants
85 Participants
n=35 Participants
178 Participants
n=76 Participants
Race/Ethnicity, Customized
American Indian
0 Participants
n=41 Participants
1 Participants
n=35 Participants
1 Participants
n=76 Participants
Race/Ethnicity, Customized
Asian
2 Participants
n=41 Participants
2 Participants
n=35 Participants
4 Participants
n=76 Participants
Race/Ethnicity, Customized
Black
17 Participants
n=41 Participants
15 Participants
n=35 Participants
32 Participants
n=76 Participants
Race/Ethnicity, Customized
White
97 Participants
n=41 Participants
97 Participants
n=35 Participants
194 Participants
n=76 Participants
Race/Ethnicity, Customized
Other
3 Participants
n=41 Participants
2 Participants
n=35 Participants
5 Participants
n=76 Participants
Race/Ethnicity, Customized
Hispanic
7 Participants
n=41 Participants
10 Participants
n=35 Participants
17 Participants
n=76 Participants
Race/Ethnicity, Customized
Not Hispanic
112 Participants
n=41 Participants
107 Participants
n=35 Participants
219 Participants
n=76 Participants
Region of Enrollment
United States
119 Participants
n=41 Participants
117 Participants
n=35 Participants
236 Participants
n=76 Participants
Cancer Site
Larynx
35 Participants
n=41 Participants
19 Participants
n=35 Participants
54 Participants
n=76 Participants
Cancer Site
Major Salivary Glands
2 Participants
n=41 Participants
6 Participants
n=35 Participants
8 Participants
n=76 Participants
Cancer Site
Oral Cavity
45 Participants
n=41 Participants
57 Participants
n=35 Participants
102 Participants
n=76 Participants
Cancer Site
Paranasal Sinuses
2 Participants
n=41 Participants
2 Participants
n=35 Participants
4 Participants
n=76 Participants
Cancer Site
Pharynx
30 Participants
n=41 Participants
25 Participants
n=35 Participants
55 Participants
n=76 Participants
Cancer Site
HNC of Unknown Primary
5 Participants
n=41 Participants
8 Participants
n=35 Participants
13 Participants
n=76 Participants
BMI
26.8 kg/m^2
STANDARD_DEVIATION 6.0 • n=41 Participants
26.5 kg/m^2
STANDARD_DEVIATION 5.9 • n=35 Participants
26.6 kg/m^2
STANDARD_DEVIATION 5.9 • n=76 Participants

PRIMARY outcome

Timeframe: Change from Baseline at 2 months, 4 months, 6 months

Population: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.

The change in average site score from baseline assessed via endoscopy using the Modified Patterson Scale. The range for each site was 0-3: Normal, Mild, Moderate, Severe. A lower score means a better outcome.

Outcome measures

Outcome measures
Measure
Advanced Pneumatic Compression Device (APCD)
n=59 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
Usual Care
n=56 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
Internal Lymphedema - Endoscopy
2-month Visit
-0.12 Score on a scale
Interval -0.38 to 0.0
-0.06 Score on a scale
Interval -0.33 to 0.11
Internal Lymphedema - Endoscopy
4-month Visit
-0.21 Score on a scale
Interval -0.44 to 0.0
-0.16 Score on a scale
Interval -0.4 to 0.0
Internal Lymphedema - Endoscopy
6-month Visit
-0.26 Score on a scale
Interval -0.53 to 0.0
-0.23 Score on a scale
Interval -0.47 to -0.01

PRIMARY outcome

Timeframe: Change from Baseline at 2 months, 6 months

Population: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.

The changes in fat stranding using the CT Lymphedema and Fibrosis Assessment Tool (CT-LEFAT). The range for fat stranding includes 0-2: Normal, Mild Changes, Advanced Changes. A lower score means a better outcome.

Outcome measures

Outcome measures
Measure
Advanced Pneumatic Compression Device (APCD)
n=90 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
Usual Care
n=62 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
Internal Lymphedema - CT Imaging
Fat Stranding Total Score Change: 2-month Visit
0.00 Score on a scale
Interval -0.17 to 0.2
0.00 Score on a scale
Interval -0.08 to 0.25
Internal Lymphedema - CT Imaging
Fat Stranding Total Score Change: 6-month Visit
0.00 Score on a scale
Interval -0.38 to 0.17
0.00 Score on a scale
Interval -0.25 to 0.25

PRIMARY outcome

Timeframe: Change from Baseline at 2 months, 6 months

Population: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.

The changes in epiglottic thickness, and prevertebral soft tissue (PVST) using the CT Lymphedema and Fibrosis Assessment Tool (CT-LEFAT). Epiglottis and PVST are measured in mm. A lower measurement means a better outcome.

Outcome measures

Outcome measures
Measure
Advanced Pneumatic Compression Device (APCD)
n=95 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
Usual Care
n=72 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
Internal Lymphedema - CT Imaging
Epiglottis Thickness Change: 2-month Visit
-0.10 mm
Interval -0.7 to 0.75
-0.20 mm
Interval -0.8 to 0.5
Internal Lymphedema - CT Imaging
Epiglottis Thickness Change: 6-month Visit
-0.60 mm
Interval -1.35 to 0.2
-0.55 mm
Interval -1.0 to 0.08
Internal Lymphedema - CT Imaging
PSVT Change: 2-month Visit
-0.40 mm
Interval -1.4 to 0.8
-0.20 mm
Interval -0.85 to 0.65
Internal Lymphedema - CT Imaging
PSVT Change: 6-month Visit
-0.60 mm
Interval -1.83 to 0.12
-1.10 mm
Interval -2.0 to -0.12

PRIMARY outcome

Timeframe: Change from Baseline at 2 months, 4 months, 6 months

Population: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.

The presence of swelling and inflammation as assessed through grading of external lymphedema via the Head and Neck Lymphedema and Fibrosis Grading criteria (HN-LEFG). A total of 9 sites are evaluated for the presence of lymphedema and graded from 1 (mild) to 3 (severe) at each site. The number of sites ranged from 0-9 with a total severity score ranging from 0-27. A lower score indicates a better outcome. A greater negative value indicates a greater reduction in swelling.

Outcome measures

Outcome measures
Measure
Advanced Pneumatic Compression Device (APCD)
n=105 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
Usual Care
n=89 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
External Lymphedema - Head and Neck Lymphedema and Fibrosis Grading
Total Score Change: 2-month Visit
-1.00 Score on a scale
Interval -2.0 to 0.0
0.00 Score on a scale
Interval -3.0 to 1.0
External Lymphedema - Head and Neck Lymphedema and Fibrosis Grading
Total Score Change: 4-month Visit
-1.00 Score on a scale
Interval -3.0 to 0.0
0.00 Score on a scale
Interval -4.0 to 1.0
External Lymphedema - Head and Neck Lymphedema and Fibrosis Grading
Total Score Change: 6-month Visit
-2.00 Score on a scale
Interval -4.0 to 0.0
-1.00 Score on a scale
Interval -3.0 to 1.0

PRIMARY outcome

Timeframe: Change from Baseline at 2 months, 4 months, 6 months

Population: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.

The presence of swelling and inflammation are assessed by digital photography. A lower value means a better outcome. A greater negative value indicates a greater reduction in swelling. Three views are scored each with 30 grids. The percentage of views with visible swelling was determined. The score ranges from 0-100%.

Outcome measures

Outcome measures
Measure
Advanced Pneumatic Compression Device (APCD)
n=102 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
Usual Care
n=86 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
External Lymphedema - Digital Photography
Front View Change: 2-month Visit
-4.55 Percent of Grids with Swelling
Interval -12.58 to 5.39
-1.38 Percent of Grids with Swelling
Interval -9.09 to 6.28
External Lymphedema - Digital Photography
Front View Change: 4-month Visit
-4.55 Percent of Grids with Swelling
Interval -11.49 to 5.89
-2.17 Percent of Grids with Swelling
Interval -11.88 to 6.72
External Lymphedema - Digital Photography
Front View Change: 6-month Visit
-4.17 Percent of Grids with Swelling
Interval -13.76 to 6.98
-1.52 Percent of Grids with Swelling
Interval -11.61 to 7.12
External Lymphedema - Digital Photography
Right View Change: 2-month Visit
-2.42 Percent of Grids with Swelling
Interval -8.44 to 5.17
-1.21 Percent of Grids with Swelling
Interval -8.47 to 5.26
External Lymphedema - Digital Photography
Right View Change: 4-month Visit
-4.63 Percent of Grids with Swelling
Interval -13.79 to 5.36
-1.39 Percent of Grids with Swelling
Interval -8.01 to 9.41
External Lymphedema - Digital Photography
Right View Change: 6-month Visit
-2.53 Percent of Grids with Swelling
Interval -11.11 to 6.82
0.00 Percent of Grids with Swelling
Interval -9.07 to 9.43
External Lymphedema - Digital Photography
Left View Change: 2-month Visit
-2.56 Percent of Grids with Swelling
Interval -10.57 to 5.46
-1.67 Percent of Grids with Swelling
Interval -8.65 to 7.34
External Lymphedema - Digital Photography
Left View Change: 4-month Visit
0.00 Percent of Grids with Swelling
Interval -8.17 to 8.23
-6.04 Percent of Grids with Swelling
Interval -14.34 to 7.58
External Lymphedema - Digital Photography
Left View Change: 6-month Visit
-2.22 Percent of Grids with Swelling
Interval -11.28 to 7.54
-3.51 Percent of Grids with Swelling
Interval -12.01 to 5.06

PRIMARY outcome

Timeframe: Change from Baseline at 2 months, 4 months, 6 months

Population: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.

Lymphedema Symptom Intensity and Distress Survey-Head and Neck (LSIDS-HN) assesses the measurement characteristics of a symptom burden for participants with head and neck lymphedema. Each symptom is rated on intensity and distress using a 5-point scale (1-Slight to 5-Severe), then added together. The values represent the mean score change from baseline. Score range: 0-10 (0 = symptom not present). A lower score means a better outcome.

Outcome measures

Outcome measures
Measure
Advanced Pneumatic Compression Device (APCD)
n=101 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
Usual Care
n=88 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
Symptom Burden - Lymphedema Symptom Intensity and Distress Survey
Total Score Change: 2-month Visit
-0.26 Score on a scale
Interval -1.5 to 0.5
-0.46 Score on a scale
Interval -1.23 to 0.33
Symptom Burden - Lymphedema Symptom Intensity and Distress Survey
Total Score Change: 4-month Visit
-0.70 Score on a scale
Interval -1.67 to 0.59
-0.71 Score on a scale
Interval -1.32 to 0.24
Symptom Burden - Lymphedema Symptom Intensity and Distress Survey
Total Score Change: 6-month Visit
-0.56 Score on a scale
Interval -1.93 to 0.46
-0.39 Score on a scale
Interval -1.32 to 0.35

PRIMARY outcome

Timeframe: Change from Baseline at 2 months, 4 months, 6 months

Population: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.

Vanderbilt Head and Neck Symptom Survey plus General Symptom Survey (VHNSS plus GSS) assesses symptom burden and functional impairment. Values represent a median score change from baseline. Score range: 0-10. A lower score indicates a better outcome. A more negative value indicates a greater change from baseline.

Outcome measures

Outcome measures
Measure
Advanced Pneumatic Compression Device (APCD)
n=102 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
Usual Care
n=89 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
Physical Function - Vanderbilt Head and Neck Symptom Survey
Total Score Change: 2-month Visit
-0.68 Score on a scale
Interval -1.38 to 0.13
-0.73 Score on a scale
Interval -1.48 to -0.09
Physical Function - Vanderbilt Head and Neck Symptom Survey
Total Score Change: 4-month Visit
-0.94 Score on a scale
Interval -1.86 to -0.1
-1.01 Score on a scale
Interval -1.6 to -0.48
Physical Function - Vanderbilt Head and Neck Symptom Survey
Total Score Change: 6-month Visit
-1.12 Score on a scale
Interval -2.34 to -0.2
-1.06 Score on a scale
Interval -1.82 to -0.43

PRIMARY outcome

Timeframe: Change from Baseline at 2 months, 4 months, 6 months

Population: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.

Quality of life is assessed using the Linear Analog Self-Assessment. The overall well-being score ranges from 0-10 (0-As bad as it can be to 10-As good as it can be). The value represents the change from baseline. A positive change indicates an improvement.

Outcome measures

Outcome measures
Measure
Advanced Pneumatic Compression Device (APCD)
n=102 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
Usual Care
n=90 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
Quality of Life - Linear Analog Self-Assessment
Total Score Change: 2-month Visit
0.00 Score on a scale
Interval -1.0 to 2.0
0.00 Score on a scale
Interval 0.0 to 1.0
Quality of Life - Linear Analog Self-Assessment
Total Score Change: 4-month Visit
0.00 Score on a scale
Interval 0.0 to 2.0
1.00 Score on a scale
Interval 0.0 to 1.0
Quality of Life - Linear Analog Self-Assessment
Total Score Change: 6-month Visit
1.00 Score on a scale
Interval 0.0 to 2.0
1.00 Score on a scale
Interval 0.0 to 2.0

PRIMARY outcome

Timeframe: Change from Baseline at 2 months, 4 months, 6 months

Population: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participants not working, participant withdrawal, or death.

Work Productivity and Activity Impairment Questionnaire (WPAIQ) PRO assessment asks questions about work and activity impairment due to lymphedema and other health problems. The values represent the difference from baseline percentage. A greater negative number indicates a greater reduction in impairment. Total score range: 0-100%

Outcome measures

Outcome measures
Measure
Advanced Pneumatic Compression Device (APCD)
n=101 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
Usual Care
n=88 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Work time missed: 2-month Visit
0.00 Percentage
Interval 0.0 to 0.0
0.00 Percentage
Interval 0.0 to 0.0
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Work time missed: 4-month Visit
0.00 Percentage
Interval 0.0 to 0.0
0.00 Percentage
Interval 0.0 to 0.0
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Work time missed: 6-month Visit
0.00 Percentage
Interval 0.0 to 0.0
0.00 Percentage
Interval 0.0 to 0.0
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Impairment while working: 2-month Visit
0.00 Percentage
Interval -20.0 to 0.0
0.00 Percentage
Interval -20.0 to 0.0
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Impairment while working: 4-month Visit
-5.0 Percentage
Interval -22.5 to 0.0
-10.0 Percentage
Interval -30.0 to 0.0
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Impairment while working: 6-month Visit
0.0 Percentage
Interval -20.0 to 0.0
0.0 Percentage
Interval -30.0 to 0.0
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Overall work impairment: 2-month Visit
0.0 Percentage
Interval -9.1 to 0.0
0.0 Percentage
Interval -20.0 to 4.1
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Overall work impairment: 4-month Visit
-5.4 Percentage
Interval -23.0 to 0.0
-12.3 Percentage
Interval -30.0 to 0.0
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Overall work impairment: 6-month Visit
0.0 Percentage
Interval -20.0 to 0.0
-6.4 Percentage
Interval -30.0 to 0.0
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Activity impairment: 2-month Visit
0.0 Percentage
Interval -30.0 to 0.0
0.0 Percentage
Interval -22.5 to 0.0
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Activity impairment: 4-month Visit
0.0 Percentage
Interval -20.0 to 0.0
0.0 Percentage
Interval -30.0 to 0.0
Work and Activity - Work Productivity and Activity Impairment Questionnaire
Activity impairment: 6-month Visit
-10.0 Percentage
Interval -30.0 to 0.0
0.0 Percentage
Interval -30.0 to 0.0

PRIMARY outcome

Timeframe: Change from Baseline at 2 months, 4 months, 6 months

Population: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.

The 8-item Perceived Medical Condition Self-Management Scale (PMCSMS) is intended to measure patients' belief that they are capable of carrying out the self-management behaviors required by their medical condition. The scale is composed of four positively worded items and four negatively worded items, each rated on a five-point Likert scale (1=Strongly Disagree to 5=Strongly Agree). Negatively worded items are reversed scored, yielding a total score ranging from 8 to 40, with a higher score indicating stronger belief of perceived self-management competence.

Outcome measures

Outcome measures
Measure
Advanced Pneumatic Compression Device (APCD)
n=102 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
Usual Care
n=89 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
Perceived Self-management Capacity - Perceived Medical Condition Self-Management Scale
Total Score Change: 2-month Visit
0.00 Score on a scale
Interval -0.38 to 0.25
0.00 Score on a scale
Interval -0.5 to 0.34
Perceived Self-management Capacity - Perceived Medical Condition Self-Management Scale
Total Score Change: 4-month Visit
0.00 Score on a scale
Interval -0.38 to 0.25
0.00 Score on a scale
Interval -0.25 to 0.38
Perceived Self-management Capacity - Perceived Medical Condition Self-Management Scale
Total Score Change: 6-month Visit
0.00 Score on a scale
Interval -0.38 to 0.25
0.00 Score on a scale
Interval -0.53 to 0.25

PRIMARY outcome

Timeframe: Change from Baseline at 2 months, 4 months, 6 months

Population: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.

Body Image Quality Life Inventory (BIQLI) assesses participants' body image using 7 point scale ranging from -3 (very negative) to +3 (very positive). Score range: -57 to +57. The values represent the change from baseline. A higher score indicates a better outcome.

Outcome measures

Outcome measures
Measure
Advanced Pneumatic Compression Device (APCD)
n=102 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
Usual Care
n=89 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
Body Image - Body Image Quality of Life Inventory
Total Score Change: 6-month Visit
4.0 Score on a scale
Interval -5.0 to 18.5
2.0 Score on a scale
Interval -3.0 to 16.2
Body Image - Body Image Quality of Life Inventory
Total Score Change: 2-month Visit
4.0 Score on a scale
Inter-Quartile Range SD • Interval -6.2 to 15.0
2.0 Score on a scale
Interval -6.2 to 14.8
Body Image - Body Image Quality of Life Inventory
Total Score Change: 4-month Visit
3.0 Score on a scale
Interval -10.5 to 17.5
2.0 Score on a scale
Interval -6.0 to 14.0

PRIMARY outcome

Timeframe: Change from Baseline at 2 months, 4 months, 6 months

Population: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.

Diet modifications will be assessed using the Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA24). The ASA24 is a tool from National Cancer Institute (NCI) that enables multiple automatically coded self-administered 24-hour recalls and food records. Changes in total caloric intake will be evaluated.

Outcome measures

Outcome measures
Measure
Advanced Pneumatic Compression Device (APCD)
n=87 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
Usual Care
n=77 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Calorie Intake: 2-mo Visit
308.0 kcal
Interval -370.0 to 755.0
182.5 kcal
Interval -338.0 to 730.0
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Calorie Intake: 4-mo Visit
212.0 kcal
Interval -265.0 to 862.5
257.0 kcal
Interval -229.5 to 905.0
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Calorie Intake: 6-mo Visit
125.5 kcal
Interval -342.0 to 698.8
18.0 kcal
Interval -541.5 to 626.0

PRIMARY outcome

Timeframe: Change from Baseline at 2 months, 4 months, 6 months

Population: The number of participants analyzed may differ from the overall number of patients analyzed due to the assessments not completed or incomplete, participant withdrawal, or death.

Diet modifications will be assessed using the Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA24). The ASA24 is a tool from National Cancer Institute (NCI) that enables multiple automatically coded self-administered 24-hour recalls and food records. Changes in total fat, carbohydrate, fiber, sugars, and protein will be evaluated.

Outcome measures

Outcome measures
Measure
Advanced Pneumatic Compression Device (APCD)
n=87 Participants
Daily self-administered treatment with the Flexitouch® Plus system (FT)
Usual Care
n=77 Participants
Complete Decongestive Therapy (CDT) directed by a lymphedema therapist and any additional adjunctive measures as prescribed by the lymphedema therapist
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Sugar Intake: 6-mo Visit
9.5 grams
Interval -17.0 to 33.8
-7.5 grams
Interval -52.2 to 31.8
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Protein Intake: 2-mo Visit
0.0 grams
Interval -33.0 to 31.0
6.5 grams
Interval -13.0 to 29.8
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Protein Intake: 4-mo Visit
5.0 grams
Interval -12.0 to 42.5
7.0 grams
Interval -30.5 to 45.5
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Protein Intake: 6-mo Visit
-1.5 grams
Interval -26.2 to 14.8
0.0 grams
Interval -24.2 to 24.0
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Fat Intake: 2-mo Visit
9.0 grams
Interval -14.0 to 36.0
13.0 grams
Interval -10.5 to 43.8
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Fat Intake: 4-mo Visit
12.0 grams
Interval -15.5 to 49.5
12.0 grams
Interval -3.5 to 51.0
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Fat Intake: 6-mo Visit
2.5 grams
Interval -19.0 to 32.2
11.5 grams
Interval -19.5 to 34.8
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Carbohydrate Intake: 2-mo Visit
36.0 grams
Interval -34.0 to 116.0
12.0 grams
Interval -45.2 to 63.0
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Carbohydrate Intake: 4-mo Visit
23.0 grams
Interval -47.5 to 94.0
3.0 grams
Interval -46.5 to 91.5
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Carbohydrate Intake: 6-mo Visit
29.0 grams
Interval -32.2 to 81.5
-8.5 grams
Interval -82.8 to 81.8
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Fiber Intake: 2-mo Visit
1.0 grams
Interval -6.0 to 5.0
1.0 grams
Interval -4.0 to 6.0
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Fiber Intake: 4-mo Visit
0.0 grams
Interval -4.0 to 6.0
2.0 grams
Interval -2.0 to 6.0
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Fiber Intake: 6-mo Visit
1.0 grams
Interval -5.0 to 7.0
0.0 grams
Interval -4.0 to 4.2
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Sugar Intake: 2-mo Visit
13 grams
Interval -14.0 to 63.0
3.0 grams
Interval -27.2 to 35.0
Diet Modifications - Automated Self-Administered 24-Hour Dietary Assessment Tool
Change in Sugar Intake: 4-mo Visit
10.0 grams
Interval -24.5 to 36.0
3.0 grams
Interval -33.0 to 40.5

Adverse Events

Advanced Pneumatic Compression Device (APCD)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 1 deaths

Usual Care

Serious events: 0 serious events
Other events: 0 other events
Deaths: 2 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Sr. VP Marketing & Clinical Affairs

Tactile Medical

Phone: 1.833.382.2845

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: LTE60